Guselkumab for moderately to severely active ulcerative colitis

被引：0
|
作者：
不详
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2025年 / 10卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [41] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Wolf, Doug
    Panaccione, Remo
    Lazar, Andreas
    Kron, Martina
    Robinson, Anne
    Thakkar, Roopal
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S20 - S21
  • [42] AN ECONOMIC EVALUATION OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM
    Diamantopoulos, A.
    Lohan, C.
    LeReun, C.
    Wright, E.
    Bohm, N.
    Sawyer, L.
    VALUE IN HEALTH, 2019, 22 : S621 - S621
  • [43] Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis - NICE guidance
    Nwaogu, Akudo
    Bond, Ashley
    Smith, Philip J.
    FRONTLINE GASTROENTEROLOGY, 2021, 12 (02) : 133 - 136
  • [44] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Wolf, Douglas
    Panaccione, Remo
    Lazar, Andreas
    Kron, Martina
    Robinson, Anne
    Thakkar, Roopal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S652 - S652
  • [45] Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
    Chen, Xinlin
    Hou, Jiangtao
    Yuan, Yujie
    Huang, Chaoyuan
    Liu, Tianwen
    Mo, Chuanwei
    Li, Haiwen
    Chen, Bin
    Xu, Qian
    Hou, Zhengkun
    He, Weiling
    Liu, Fengbin
    BIODRUGS, 2016, 30 (03) : 207 - 217
  • [46] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 213 QUASAR STUDY RESULTS THROUGH WEEK 12
    Allegretti, Jessica R.
    Rubin, David T.
    Bressler, Brian
    Huang, Kuan-Hsiang G.
    Shipitofsky, Nicole
    Germinaro, Matthew
    Zhang, Hongyan
    Johanns, Jewel
    Feagan, Brian
    Sandborn, William J.
    Sands, Bruce E.
    Hisamatsu, Tadakazu
    Lichi, Gary R.
    Lichtenstein, Gary R.
    Panes, Julian
    Dignass, Axel
    GASTROENTEROLOGY, 2022, 162 (07) : S963 - S964
  • [47] Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study
    Sridhar, S.
    Hart, A.
    Venkat, S.
    Huang, K. H. G.
    Yarandi, S.
    Germinaro, M.
    Vetter, M.
    Rubin, D. T.
    Dignass, A.
    Cua, D.
    Freeman, T.
    Waterworth, D.
    Mcrae, B.
    Verstockt, B.
    Branigan, P.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i422 - i422
  • [48] Guselkumab for ulcerative colitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 972 - 972
  • [49] Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
    Rubin, D.
    Sands, B.
    Lichtenstein, G.
    Baker, T.
    Huang, K. H.
    Germinaro, M.
    Miao, Y.
    Zhang, H.
    Nancey, S.
    Allegretti, J.
    Feagan, B.
    Hisamatsu, T.
    Panes, J.
    Dignass, A.
    Bressler, B.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1722 - I1723
  • [50] Guselkumab improves abdominal pain and bowel urgency symptoms in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
    Rubin, D.
    Panes, J.
    Feagan, B.
    Yarandi, S.
    Huang, K. H.
    Germinaro, M.
    Han, C.
    Miao, Y.
    Zhang, H.
    Qiu, Y.
    Klopocka, M.
    Duvall, G.
    Lichtenstein, G.
    Hisamatsu, T.
    Bressler, B.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1816 - I1817
12345